The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the rapid evolution of the weight-loss drug market, Novo Nordisk has received European Union approval for the first oral tablet version of its Wegovy obesity treatment. This approval by the European Commission marks a strategic shift from injectable-only options to oral alternatives. The expansion aims to reach a broader patient base preferring oral administration, though the market continues to weigh this development against increasing competition within the GLP-1 drug class.
Recent data reveals significant market dominance, with oral Wegovy capturing approximately 89% of new U.S. prescriptions compared to 11% for Eli Lilly's competing product. The drug recorded 153,050 weekly prescriptions versus 19,550 for its rival, with over 80% of these prescriptions coming from new GLP-1 patients rather than cannibalizing existing sales. This surge comes as Eli Lilly's Zepbound recorded $1.24 billion in Q1 sales per company reports, highlighting the intense competition in a sector Goldman Sachs projects will reach $100 billion by the end of the decade.
Regarding stock performance, NVO shares stood at $51.48 at the close of July 16, 2026, per market data. Traders are currently watching support levels near the recent daily low of $50.60. While there are no immediate company-specific catalysts in the upcoming economic calendar, the release of US Inflation (CPI) data on July 14 remains a broader macro factor that could influence sentiment across the healthcare sector.